Reuters logo
BRIEF-AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis
October 10, 2017 / 10:45 AM / 2 months ago

BRIEF-AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis

Oct 10 (Reuters) - AnaptysBio Inc:

* AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis

* AnaptysBio Inc - ‍83 percent of patients achieved EASI-50 at day 29 following a single dose of ANB020​

* AnaptysBio Inc - ‍ANB020 was generally well tolerated in all patients as of this interim analysis​

* AnaptysBio-Continues to advance its ongoing ANB020 phase 2A studies in adults with severe peanut allergy with topline data expected in Q4 of 2017​

* Anaptysbio Inc - ‍during first half of 2018, co plans to initiate a phase 2B randomized, double-blinded, placebo-controlled study​

* AnaptysBio Inc - no severe adverse events have been reported to date on ‍ANB020 ​

* AnaptysBio- also continues to advance ongoing ANB020 phase 2A studies in adults with severe eosinophilic asthma, topline data expected in first half of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below